key: cord-0918390-fifqqu2e
authors: Griffiths, P. D.
title: Vaccines for SARS coronavirus 2 and the new normal in vaccinology
date: 2021-03-05
journal: Rev Med Virol
DOI: 10.1002/rmv.2229
sha: 7005611327527b39365f18d8989da78330266a35
doc_id: 918390
cord_uid: fifqqu2e

nan

The virus has a dominant surface protein that is highly immunogenic and it can be presumed that neutralising antibodies will prove to be the correlate of protection, supported by cell-mediated immunity. 1 It should therefore be straightforward to produce a vaccine against this novel virus.

This perspective has turned out to be true, but it is the pace with which the vaccines have been prepared and delivered that is spectacular. Consider that the vaccine made against the 2009 influenza H1N1 pandemic virus was delivered in record time, yet the first wave of cases had been and gone before it could be deployed. 2 Influenza vaccine has the distinct advantage that its licensure is based on a variation from the existing product licence and so can circumvent much of the long, detailed regulatory review needed for a new vaccine. Credit should be given to the flexibility shown by expert regulators prepared to conduct rolling review of the process of licencing each SARS-CoV-2 vaccine rather than waiting for massive files of data to be delivered to them at one timepoint. Major credit should also be given to the developers of novel vaccine platforms who accelerated their plans to bring us vaccines to protect against coronavirus disease 2019 (Covid-19) well before the traditional methodology, such as killed vaccine, liveattenuated vaccine or recombinant glycoprotein plus adjuvant were able to deliver. One platform is based on RNA technology while the second utilises recombinant adenovirus, neither of which has previously led to a licenced vaccine product. [3] [4] [5] [6] By modifying RNA to enhance expression of the encoded desired immunogen, a chemically defined path to making vaccines from far fewer and less complex molecules has been provided, including the characteristic of self-amplification by including the option of encoding an RNA polymerase within the RNA molecule. 7 Degradation after injection is reduced and uptake into target cells is increased by physical incorporation of the modified RNA into lipid nanoparticles. My preference for the next acute virus infection spread by the respiratory route that causes serious disease with unmet medical need and has a prominent glycoprotein protruding through its lipid envelope would be respiratory syncytial virus, but readers may prefer alternative targets.

Correspondence Email: p.griffiths@ucl.ac.uk

Emergence of novel coronavirus and progress toward treatment and vaccine

Influenza: options to improve pandemic preparation

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Opportunities and challenges in the delivery of mRNA-based vaccines